

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

The orange spotted cockroach (*Blaptica dubia*, Serville 1839) is a permissive experimental host for *Francisella tularensis*.

Bridget E. Eklund^{1,2}, Tricia Gilson³, Osama Mahdi², Jason F. Huntley⁴,
Joseph Horzempa³, and Nathan A Fisher^{5,6*}

¹ Russel and Anna Duncan Undergraduate Research Program, College of Agriculture, Food Systems and Natural Resources, North Dakota State University, Fargo, ND

² Department of Veterinary and Microbiological Sciences, North Dakota State University, Fargo, ND

³ Department of Natural Sciences and Mathematics, West Liberty University, West Liberty, WV

⁴ Department of Medical Microbiology and Immunology, University of Toledo, Toledo, OH

⁵ Department of Public Health, North Dakota State University, Fargo, ND

⁶ Drug Development Division, Southern Research, Frederick, MD

*To whom correspondence should be addressed: nfisher@southernresearch.org

3/2/2016

25 **1 Abstract**

26 *Francisella tularensis* is a zoonotic bacterial pathogen that causes severe disease in a wide
27 range of host animals, including humans. Well-developed murine models of *F. tularensis*
28 pathogenesis are available, but they do not meet the needs of all investigators. Instead,
29 researchers are increasingly turning to insect host systems to: (1) allow high-throughput that is
30 cost-prohibitive or ethically-questionable in mammals; (2) enable studies of host-pathogen
31 interactions when mammalian facilities are unavailable; and (3) provide valuable information
32 about environmental persistence and transmission. However, the utility of previously-
33 described insect hosts is limited because of temperature restriction, short lifespans, and
34 concerns about the immunological status of insects mass-produced for other purposes. Here,
35 we present a novel host species, the orange spotted (OS) cockroach (*Blaptica dubia*), that
36 overcomes these limitations and is readily infected by *F. tularensis*. Intrahemocoel
37 inoculation was accomplished using standard laboratory equipment and lethality was directly
38 proportional to the number of bacteria injected. Progression of infection differed in insects
39 housed at low and high temperatures, a pattern indicative of a switch between virulence and
40 transmission phenotypes. As in mammalian hosts, *F. tularensis* mutants lacking key virulence
41 components were attenuated in OS cockroaches. Finally, antibiotics were delivered to infected
42 OS cockroaches by systemic injection and controlled feeding; in the latter case, protection
43 correlated with oral bioavailability in mammals. Collectively, these results demonstrate that
44 this new host system should facilitate discovery of factors that control *F. tularensis* virulence,
45 immune evasion, and transmission while also providing a platform for early stage drug
46 discovery and development.

47 **2 Introduction**

48 *Francisella tularensis* is a Gram-negative bacterial pathogen capable of causing disease in a
49 remarkably diverse array of hosts; at least 190 different species of mammals, 23 birds, 3

50 amphibians and 88 invertebrates are recognized as being susceptible to *F. tularensis* infection
51 [1]. In addition, *F. tularensis* utilizes a wide variety of environmental arthropod vectors for
52 transmission [2-10]. In experimental animals, *F. tularensis* invades and replicates within both
53 phagocytic and non-phagocytic cells [11-14] and several studies have demonstrated that *F.*
54 *tularensis* survives engulfment by bacterivorous protists, often escaping from the food vacuole
55 and replicating within the cytosol [15-17]. This ability to survive intracellularly is thought to
56 contribute to the low infectious dose of *F. tularensis*, which is fewer than 10 bacteria for the
57 highly-virulent strains [18]. Due to this high infectivity and an accompanying high rate of
58 mortality and morbidity, *F. tularensis* is of particular concern as an agent of biological terrorism
59 and is therefore classified as a Tier 1 select agent by the US Centers for Disease Control [19].
60 An attenuated live vaccine strain (LVS) originally was derived from a virulent isolate in the
61 1950s [20]. Despite its name, LVS is not currently approved by the US Food and Drug
62 Administration for standard human use because of safety and efficacy concerns. However, the
63 LVS strain can be manipulated in biosafety level two laboratories (BSL2) and still causes rapid
64 and severe disease in many hosts, allowing for *F. tularensis* pathogenesis studies without the
65 need for BSL3 containment.

66 While experimental models of infectious disease historically have been developed around
67 mammalian host species, non-vertebrate hosts continue to gain attention as an alternative
68 approach for studying pathogenic microorganisms [21-24]. In particular, studies using the fruit
69 fly *Drosophila melanogaster* [25, 26] and Greater Wax Moth *Galleria mellonella* larvae [27-
70 29] have significantly advanced our understanding of *F. tularensis* pathogenesis. *D.*
71 *melanogaster* offers powerful host genetic tools but the small body size of this insect makes
72 delivering an exact dose of bacteria difficult without specialized equipment and training.
73 Moreover, *D. melanogaster* is temperature-restricted and cannot survive at typical mammalian
74 body temperatures, making this host of limited use for analysis of pathogens with temperature-

75 sensitive virulence patterns such as *F. tularensis* [30]. In contrast, *G. mellonella* survives well
76 at 37°C and is large enough for confident dosing with a small-gauge syringe. *G. mellonella*
77 larvae also are readily-available in large quantities from a number of commercial suppliers.
78 However, this insect host also requires investigators to accept certain limitations and tradeoffs.
79 Pupation, the process by which the larvae metamorphose into adults, typically occurs within
80 a short period of time when the larvae are kept at 37°C, thereby limiting the experimental
81 window available to researchers. Immune function can vary widely before, during, and after
82 pupation [31-33], thus making it difficult to standardize host immunological status in *G.*
83 *mellonella*. When working with *G. mellonella* from commercial suppliers, we encountered
84 tremendous shipment-to-shipment variability in experimental outcome, presumably due to
85 differences in the general health status of the larvae. Other groups have observed similar trends
86 and have addressed this concern by supplementing the insect meal with antibiotics [34] or
87 setting a mortality threshold in control groups that, when surpassed, allows investigators to
88 discard the results and repeat the experiment with a new batch of insects [35-37]. Dissatisfied
89 with these options, we began to rear *G. mellonella* in the laboratory so that we could better
90 control their quality. We were surprised to find that, in contrast to larvae purchased from
91 commercial sources, those reared in the lab quickly became encased in silk when transferred
92 from the rearing vessel to a Petri plate for experimental manipulation (**Figure 1A** and **1B**).
93 Others have reported a similar cocoon in laboratory-reared insects and recommend that larvae
94 be mechanically removed from the structure prior to infection [24]. However, we found it
95 difficult to perform this procedure without causing physical trauma to the larvae. Moreover,
96 larvae would generally spin a new cocoon within a matter of hours, making it necessary to
97 perform this manipulation each day of the study in order to observe the larvae for mortality.
98 Thus when using laboratory-reared *G. mellonella* larvae, the throughput advantage of an insect
99 model is compromised by this cumbersome procedure. In search of an explanation for this

100 behavioral difference between commercially-obtained *G. mellonella* and those reared in the lab,
101 we found two on-line forums for hobbyists that described the use of a brief freeze treatment to
102 destroy the silk gland [53, 54]. Although we were unable to confirm that commercial suppliers
103 of *G. mellonella* use this particular method, it is clear that they treat their insects in some way
104 that prevents silk production. While this does aid in handling and improves experimental
105 throughput, it is problematic for pathogenesis studies because the immunological consequences
106 of a necrotic silk gland are unknown. On the one hand, necrosis could activate a generalized
107 immune response [38]. Alternatively, the silk gland is an important component of the
108 antibacterial immune response in wax worms [31] and its loss or dysregulation could impair
109 functional immune responses in this host. Given these inherent problems with the *G. mellonella*
110 model, we sought to identify another insect host that is simple and inexpensive to rear in the
111 laboratory, survives well at 37°C for long periods of time, and is large enough to allow
112 inoculation with known doses of bacteria without specialized equipment.

113 We previously determined that the Madagascar hissing (MH) cockroach (*Gromphadorhina*
114 *laevigata*) met the above noted criteria and was a suitable surrogate host for the facultative
115 intracellular pathogens *Burkholderia mallei*, *B. pseudomallei*, and *B. thailandensis* [39]. Here,
116 we sought to determine if tropical cockroach species can serve as experimental hosts for another
117 important bacterial pathogen, namely *F. tularensis*. The Orange Spotted (OS) cockroach
118 (**Figure 1C**, *Blaptica dubia* Serville 1839) also meets the above criteria as an ideal insect host
119 for pathogenesis studies but is more readily available from commercial suppliers and is more
120 docile compared to the MH cockroach. The OS cockroach does not vocalize like the MH
121 cockroach and it usually remains in an immobile defensive position when placed on its back.
122 Of interest to researchers who desire to rear their own host animals, the OS cockroach does not
123 climb vertical glass or plastic surfaces, which aids in containment of the cockroaches in their
124 rearing containers. The body size and sclerotised cuticle of OS cockroach enables

125 intrahemocoel inoculation using either a standard needle and syringe combination or a
126 sharpened pipette tip (**Figure 1D**), which improves laboratory safety and decreases costs. We
127 found the OS cockroach to be a permissive host for *F. tularensis* LVS. Lethality depended upon
128 the dose of bacteria given, the temperature of incubation, and, interestingly, the developmental
129 stage and gender of the cockroach. Bacterial titers increased throughout the course of infection
130 and several mutant strains lacking factors known to be involved in *Francisella* pathogenesis
131 were attenuated. Infection could be rescued by systemic or peroral delivery of antibiotics, with
132 protection by the peroral route correlating with known oral absorption profiles in mammals.
133 These results extend our previous findings [39] and demonstrate that tropical cockroaches are
134 a favorable alternative to mammals and other insect species for the study of multiple bacterial
135 pathogens.

136 **3 Results**

137 **3.1 Infection of OS cockroaches with *F. tularensis* LVS**

138 To determine if OS cockroach survival was proportional to the number of bacteria present in
139 the inoculum, serial dilutions of *F. tularensis* LVS were injected into the hemocoel of juvenile
140 cockroaches that weighed between 0.7 and 1.0 grams. Following infection, cockroaches were
141 housed at 37°C and survival was monitored over the course of 7 days. Overall, the percentage
142 of cockroaches in each group that survived infection and the rates of death were dose-
143 dependent. None of the cockroaches inoculated with 10⁶ or 10⁵ CFU of *F. tularensis* LVS
144 survived beyond day 4 (**Figure 2**). In comparison, 5 out of 8 cockroaches infected with 10⁴
145 CFU of *F. tularensis* LVS survived through day seven post-infection (p=0.0141; compared to
146 10⁵ CFU group) and 7 out of 8 cockroaches infected with 10³ CFU of *F. tularensis* LVS survived
147 through day seven post-infection (p<0.001; compared to 10⁵CFU group). Injection of PBS alone
148 did not result in any cockroach deaths.

149 **3.2 Effect of temperature on *F. tularensis* virulence**

150 Transcriptional activation of *F. tularensis* virulence factors is at least partially controlled by
151 temperature [30]. This is particularly interesting given that *F. tularensis* is well-known to be
152 transmitted to mammals by ticks and other arthropod vectors [2-10] and, thus, the bacterium
153 encounters dramatically different temperatures in its varied hosts. Since insects are ectothermic,
154 taking on the ambient temperature of their surroundings, we sought to determine the impact of
155 varied temperatures on *F. tularensis* pathogenesis in this system. Serial dilutions of *F. tularensis*
156 were injected into the hemocoel of juvenile OS cockroaches and their survival rates were
157 monitored over the course of 8 days at 22°C, 30°C, 37°C, or 40°C. Overall, we found that higher
158 temperatures correlated with higher LVS virulence in the OS cockroach (**Figure 3, Table 1**).
159 Following infection with 10⁶ CFU, incubation at either 37°C or 40°C resulted in rapid OS
160 cockroach death (mean time-to-death of 3.6 and 3.2 days, respectively), with no survivors at
161 either temperature (**Figure 3**). By comparison, incubation at the lower temperatures of 22°C or
162 30°C resulted in delayed time-to-death and increased survival, despite slightly higher inoculums
163 (**Figure 3**). At 30°C, 20 percent of cockroaches survived *F. tularensis* LVS infection with a
164 mean time-to-death of 6.14 days. At 22°C, 30 percent of cockroaches survived *F. tularensis*
165 LVS infection with a mean time-to-death of 6.33 days. There were no significance differences
166 between cockroach survival at 22°C and 30°C or between cockroach survival at 37°C and 40°C.
167 However, cockroach survival at both of the lower temperatures (22°C and 30°C) was
168 significantly different from cockroach survival at both of the higher temperatures (37°C and
169 40°C; all p<0.001).

170 **3.3 *F. tularensis* genes required for virulence in mammals are** 171 **required for virulence in OS cockroaches**

172 In order to determine if virulence factors known to be required for *F. tularensis* pathogenicity
173 in mammals also are required in our cockroach model, we determined the LD₅₀ value for several

174 mutant strains of *F. tularensis* LVS. Juvenile OS cockroaches were infected by intrahemocoel
175 injection followed by incubation at 37°C. Survival was monitored for 8 days post-infection and
176 the LD₅₀ value for each strain was determined by non-linear regression. Since the various LVS
177 mutants were generated by two different laboratories, we excluded the possibility of inherent
178 differences in LVS virulence by infecting cockroaches with either LVS parental strain, LVS-1
179 and LVS-2. Indeed, LVS-1 and LVS-2 did not exhibit any significant LD₅₀ differences in
180 juvenile cockroaches at 37°C (**Table 1**). In contrast, loss of *dsbA*, *dipA*, *iglC*, or *deoB* resulted
181 in substantially decreased virulence in cockroaches (**Table 1**), similar to trends previously
182 observed in mice [41-44] and chick embryos [30]. More specifically, *dipA* and *deoB* mutants
183 were more than 1-log attenuated in cockroaches and *dipA* and *iglC* were nearly 2-log attenuated
184 in cockroaches. These results suggest that, despite obvious differences between mice and
185 cockroaches, there are significant overlaps in how *F. tularensis* causes disease and death in
186 hosts from diverse phyla.

187 **3.4 In vivo growth of *F. tularensis* LVS**

188 In order to monitor the kinetics of *F. tularensis* LVS growth during infection, we harvested
189 hemolymph from infected OS cockroaches at various time points post-infection and used serial
190 dilution to enumerate the number of viable bacterial cells in each sample. In one set of
191 experimentally infected cockroaches, we measured the total number of bacteria present at each
192 time point. After an initial inoculum of 10⁶ CFU, *F. tularensis* LVS quickly replicated, reaching
193 10⁹ CFU per ml of hemolymph by 96 hours (**Figure 4**). Since the antibiotic gentamicin does
194 not penetrate eukaryotic host cells, it is lethal only to extracellular bacteria [25, 45]. Therefore,
195 we administered it to a second set of infected cockroaches 2 hours prior to harvesting
196 hemolymph in order to distinguish between *F. tularensis* LVS cells located in intracellular and
197 extracellular environments. Interestingly, most bacteria in the hemolymph were sensitive to

198 gentamicin, indicating that they were exposed to the extracellular environment at some time
199 during the 2 hours prior to harvest (**Figure 4**).

200 **3.5 Effect of OS cockroach development on *F. tularensis*** 201 **virulence**

202 Because insect immune responses are known to vary by age and developmental stage [46-48],
203 we sought to determine if there were any differences in susceptibility to *F. tularensis* LVS in
204 juvenile and adult cockroaches. Injections in adults were performed using the same method
205 described for the juveniles. Cockroaches cannot be separated by gender as juveniles, but
206 anatomical differences (**Figure 1C**) make gender determination possible in adults. We,
207 therefore, analyzed survival in adult female and adult male cockroaches separately. We found
208 that although the overall percentages of surviving cockroaches differed slightly between adult
209 female (50 percent survival) and juvenile (30 percent survival) cockroaches, both groups were
210 equally susceptible to *F. tularensis* LVS infections (juvenile mean time-to-death 4.7 days; adult
211 female mean time-to-death 4.8 days; no statistical difference between groups). By comparison,
212 adult male cockroaches were more sensitive to killing by *F. tularensis* LVS, with rapid death
213 rates (mean time-to-death 3.8 days) and 100% mortality by day 6 post-infection ($p=0.0169$
214 compared with juveniles; $p<0.001$ compared with adult females; **Figure 5**). The LD_{50} of adult
215 males was determined to be 1.3×10^3 CFU, which is a 1.4- and 1.6-log decrease from that of
216 juvenile and adult female cockroaches, respectively (**Table 1**).

217 **3.6 Antibiotic rescue of infected OS cockroaches**

218 To explore whether OS cockroaches may be useful in the drug development pipeline, we
219 infected cockroaches with a high dose (1.3×10^6 CFU to 3.4×10^6 CFU) of *F. tularensis* LVS
220 by intrahemocoel injection and then administered antibiotics either by injection or by controlled
221 feeding (**Figure 6**). All cockroaches in the vehicle only control groups died by day 7 post-
222 infection (**Table 2**). Doxycycline, an antibiotic known to absorb well through mucus

223 membranes, effectively prevented cockroach death when delivered by either route (**Table 2**,
224 $p < 0.001$). *F. tularensis* LVS is resistant to azithromycin [49] and this antibiotic failed to protect
225 OS cockroaches from infection, illustrating the specificity of protection in the assay (**Table 2**).
226 Streptomycin and gentamicin, which have poor oral bioavailability in mammals, were effective
227 at preventing cockroach mortality when injected directly into the hemocoel (80 percent survival
228 with streptomycin; 90 percent survival with gentamicin; $p < 0.001$ for both antibiotics compared
229 to no antibiotic treatment; **Table 2**). However, neither of these antibiotics rescued OS
230 cockroaches when delivered perorally ($p = 0.00199$ for injection of streptomycin compared to
231 forced feeding; $p < 0.001$ for injection of gentamicin compared to forced feeding). Finally,
232 Resazurin, an experimental drug candidate that has anti-*F. tularensis* activity *in vitro* [50],
233 failed to protect OS cockroaches from infection (no survival by either delivery route; **Table 2**).

234 4 Discussion

235 *F. tularensis* is a highly-virulent zoonotic pathogen that causes significant morbidity and
236 mortality globally. To facilitate future advances in our understanding of this important
237 bacterium, we sought to develop an improved insect host system that eliminates undesirable
238 biological and logistical trade-offs that accompany other popular host species such as *D.*
239 *melanogaster* and *G. mellonella*. While insects lack adaptive immune functions, their innate
240 immune systems share similar regulation and effector mechanisms with mammalian innate
241 immune systems [21-24]. Because of this, insects can provide investigators with a host-
242 pathogen interaction system capable of high-throughput that would be either financially or
243 ethically unacceptable in mammals. Importantly, insects also provide scientists at institutions
244 that lack access to mammalian housing facilities an alternative means by which to assess *in*
245 *vivo* host-pathogen interactions. Finally, insects and other arthropods can be important
246 environmental reservoirs and vectors for numerous zoonotic pathogens, including *F.*

247 *tularensis*. Thus, insect host systems also aid in illuminating how these microorganisms evade
248 arthropod immune systems during this part of their lifecycle without the necessity of rearing
249 sanguinivorous arthropods in the lab. Here, we sought to identify an experimental host for *F.*
250 *tularensis* that is (1) readily-available, (2) simple to rear in the laboratory, (3) tolerant of
251 mammalian body temperatures, (4) large enough in size to allow consistent delivery of
252 bacterial inoculations using standard needle-syringe combinations, (5) long-lived with low
253 background mortality, and (6) hardy enough to withstand multiple injections of bacteria
254 and/or antibiotics. We found that the *B. dubia* OS cockroach satisfied all of these
255 requirements.

256 Like fruit flies and wax moth larvae, OS cockroaches are readily available. Several strain
257 repositories supply the scientific community with *D. melanogaster* seed stocks and in-house
258 rearing is easily accomplished using well-established protocols [51, 52]. Unfortunately, *D.*
259 *melanogaster* does not tolerate incubation at mammalian body temperatures and quantitative
260 infection requires highly specialized equipment. Thus, we did not consider *D. melanogaster* for
261 our studies. In contrast, both *G. mellonella* and *B. dubia* survive at mammalian body
262 temperatures. Critically, both of these hosts are able to mount effective immune responses
263 against non-pathogenic microorganisms while infection by *F. tularensis* results in dose-
264 dependent mortality ([29]; **Figure 1** and **Table 1**). Thus, *F. tularensis* LVS is able to evade
265 active immune functions and establish a lethal infection in both of these experimental hosts.

266 Unfortunately, suppliers of wax worms and OS cockroaches are generally focused on non-
267 scientific audiences. Wax worms are a popular choice for fishing bait and both wax worms and
268 OS cockroaches are used as food for captive reptiles. In these markets, easy handling by
269 consumers is critically important. This has led commercial suppliers to inactivate the wax worm
270 silk gland by some unknown procedure (possibly using a freeze treatment as described by
271 hobbyists in online forums [53, 54]). The physiological and immunological impacts of silk

272 gland dysfunction are unknown, but it is clear that this organ is an important part of the antibacterial
273 response in wax worms [31]. To avoid this serious complication for pathogenesis studies, wax
274 worms can be reared in the laboratory [24] but we found it difficult to consistently do so without
275 microbial contamination, a factor that might contribute to unpredictable rates of background
276 mortality in our and others' studies [34-37]. In contrast, maintenance of a cockroach breeding
277 colony in the laboratory is simple and straightforward [55, 56]. Compared to other cockroach
278 species, OS cockroaches are docile and easy to handle. They are relatively slow, remain
279 immobile when placed on their back, do not climb vertical glass or plastic surfaces, and they do
280 not fly. It is unclear if these are characteristics of wild OS cockroaches or if they have been
281 selected during captive breeding. Importantly, a minimal amount of maintenance is required to
282 prevent microbial contamination (and odor) in OS cockroach breeding colonies. As a result, we
283 rarely observe mortality in uninfected control groups of OS cockroaches (**Figure 1** and **Table**
284 **2**).

285 Both wax worms and cockroaches can be infected with known doses of microorganisms
286 using needle and syringe combinations [24, 39]. But unlike wax worms, OS cockroaches can
287 also be infected using sharpened gel-loading pipette tips, which increases the safety and
288 decreases the cost associated with pathogenesis studies in this host. After infection, wax worms
289 can survive at least one subsequent administration of antibiotics [29, 35]. Here, we established
290 that OS cockroaches can tolerate at least 3 injections following infection without an increase in
291 background mortality (**Table 2**). Importantly, the experimental window available to
292 investigators is substantially different between wax worms and OS cockroaches. OS
293 cockroaches undergo incomplete metamorphosis, with each developmental stage (or instar)
294 lasting between 20 and 45 days. In total, it takes approximately 6 months for OS cockroaches
295 to reach adulthood. The juvenile cockroaches used in this study were infected during the 6th
296 instar (next to last), leaving between 30 and 60 days of experimental observation before they

297 would have molted into the adulthood. In contrast, we often observed that considerable fractions
298 (>25% in some cases, data not shown) of wax moth larvae pupated during a typical 7 day
299 survival experiment. This is troublesome for studies of host-pathogen interactions because wax
300 worm immune responses are known to vary throughout the period leading up to pupation [57].
301 Thus, small differences in individual age may impact the immune status of wax worms. While
302 we did observe that adult male cockroaches were more susceptible to *F. tularensis* (**Figure 5**),
303 the similarity between mortality in juvenile and adult female cockroaches indicates that small
304 differences in age are unlikely to effect experimental results in this system. Collectively, these
305 differences demonstrate that OS cockroaches offer important improvements compared to wax
306 worms for studies of microbial pathogenesis. Thus, we went on to characterize several relevant
307 factors in this model, including the impact of temperature on virulence, *in vivo* growth, genetic
308 requirements for bacterial virulence, and the usefulness of the model for pharmacological
309 screening.

310 Temperature is known to regulate expression of *F. tularensis* virulence factors [30]. One of
311 the advantages of insect models, in comparison with mammals, is the ability to experimentally
312 manipulate the temperature at which host-pathogen interactions occur. When we varied the
313 temperature at which infection took place, we observed that higher temperatures correlated with
314 higher mortality (**Figure 2, Table 1**). Others have shown that temperature can effect insect
315 immune pathways [58-62], and there may be some differences in the immune response of OS
316 cockroaches infected at different temperatures. However, it is intriguing to consider that, since
317 *F. tularensis* can be spread by environmental arthropods [2-10], temperature may provide an
318 important environmental cue that allows *F. tularensis* to dampen virulence pathways that would
319 otherwise kill these vectors before they have an opportunity to transmit the bacterium to a
320 subsequent host mammal. Thus, the OS cockroach system is an attractive new platform with

321 which to interrogate the important but understudied environmental stage of the *F. tularensis*
322 lifecycle and the switch between mammalian and arthropod hosts.

323 We took a genetic approach to test the hypothesis that virulence toward OS cockroaches at
324 37°C mimics virulence toward mammals. We examined the virulence of a small panel of *F.*
325 *tularensis* LVS mutants that are attenuated in other model systems. DsbA and DipA are both
326 associated with the normal structure and function of the *F. tularensis* membrane and their loss
327 results in severe attenuation in mammals [42, 43]. DeoB is a metabolic protein (a
328 phosphopentomutase) required for cellular invasion and virulence toward macrophages,
329 dendritic cells, and chick embryos in *F. tularensis* [30, 63] and virulence toward mice in the
330 closely related *Francisella novicida* [64]. Finally, IglC is a virulence factor encoded on the
331 *Francisella* pathogenicity island that is required for intracellular survival and virulence toward
332 mice [65, 66, 44]. We found that mutants lacking each of these proteins are also attenuated in
333 OS cockroaches (**Table 1**). Since these proteins play essential roles in distinct components of
334 the *F. tularensis* virulence program, this finding supports the idea that *F. tularensis* uses similar
335 mechanisms to evade immune clearance and cause disease in extremely diverse host organisms.
336 Thus, the OS cockroach model should be useful in identifying additional regulators and
337 effectors of *F. tularensis* pathogenesis.

338 Classically, *F. tularensis* is considered a facultative intracellular pathogen and it is known
339 to invade both mammalian and insect cells [25, 28, 45]. As seen in **Figure 4**, gentamicin-
340 resistant bacteria can be recovered as early as six hours post injection, which is likely to indicate
341 successful invasion of OS cockroach cells as has been previously reported for *D. melanogaster*
342 [25]. As expected, the population of intracellular bacteria continues to grow throughout the
343 infection process. Interestingly, the majority of *F. tularensis* cells recovered at each time point
344 were killed by injection of gentamicin prior to harvest, indicating that they were located in the
345 extracellular environment. This finding mirrors what others have observed for *F. novicida* in

346 *D. melanogaster* [25]. Since administration of gentamicin rescued OS cockroaches from
347 lethality (**Table 2**), the extracellular *F. tularensis* population appears to be essential to the
348 infection process, as has been recently suggested elsewhere [67]. While the intracellular phase
349 of *F. tularensis* pathogenesis is well-appreciated, our findings suggest that the OS cockroach
350 may be a useful model for elucidating the mechanisms by which *F. tularensis* survives, grows,
351 and moves within the extracellular environment.

352 Host immune function is not static; it can vary dramatically across developmental stages in
353 wax worms and other lepidopterans [57, 46, 68] and fruit flies [69, 70]. Importantly, Meylaers,
354 et al, found that wax worm immunity dramatically increases as larvae progress through the
355 wandering stage, in which they are typically used, and enter pupation [57]. We therefore sought
356 to determine if OS cockroach susceptibility to *F. tularensis* LVS varied by developmental stage.
357 We determined the killing kinetics and LD₅₀s of *F. tularensis* LVS against juvenile, adult
358 female, and adult male OS cockroaches. The susceptibility pattern of juveniles (which we used
359 for all other experiments reported here) and adult females were highly similar. In comparison,
360 adult males showed enhanced susceptibility, with a shorter mean time-to-death (**Figure 4**) and
361 a lower LD₅₀ (**Table 1**). The reason for increased susceptibility in adult males is currently
362 unknown and could result from either decreased resistance to *F. tularensis* or decreased
363 tolerance to damage that occurs during infection. Interestingly, Horn, et al, found that the
364 phagocytic ability of *D. melanogaster* hemocytes, migratory cells similar in function to
365 mammalian macrophages, decreases with age [69] and it will be interesting to examine this and
366 other possible causes of the increased susceptibility that we observed in adult males. Revealing
367 these causes may illuminate key host factors that differentiate protective and unprotective
368 immune responses to *F. tularensis* infection, information that could aid in developing a much-
369 needed safe and effective vaccine.

370 Finally, we tested the ability of five different antibiotics to protect OS cockroaches from *F.*
371 *tularensis* LVS infection (**Table 2**). Doxycycline is readily absorbed orally and was able to
372 protect OS cockroaches from infection when delivered by either route. This protection was
373 specific to antibiotics with anti-*Francisella* activity since azithromycin, to which *F. tularensis*
374 LVS is resistant, failed to protect from lethality. Streptomycin and gentamicin are
375 aminoglycoside antibiotics with poor oral bioavailability in mammals. Interestingly, these
376 antibiotics only protected OS cockroaches when delivered by systemic injection and not when
377 provided perorally. These findings indicate that oral absorption of antibiotics is similar in both
378 mammals and insects and that OS cockroaches can provide a preliminary screening platform
379 for identification of new antibiotics with anti-*Francisella* activity. As an example, we examined
380 the ability of resazurin, which has been shown to have potent anti-*F. tularensis* LVS activity *in*
381 *vitro* [50], to rescue OS cockroaches from lethality. Unfortunatley, resazurin failed to protect
382 OS cockroaches from infection. Thus, we hypothesize that further modifications of the
383 resazurin chemical backbone, something we are currently pursuing, will be required in order
384 establish *in vivo* anti-*Francisella* activity. It is thought-provoking to consider how screening for
385 *in vivo* activity in insects prior to substantial investments in mammalian models could change
386 the cost profile of early stage antibiotic development efforts.

387 We suggest that, collectively, these results show that the OS cockroach offers significant
388 biological and logistical advantages compared to other experimental host choices. Further, the
389 OS cockroach will allow for characterization of virulence and transmission pathways within a
390 single host including identification of *F. tularensis* genes required for these processes,
391 dissection of effective and ineffective immune responses within a single host species, and pre-
392 mammalian screening of therapeutic candidates. Thus, the OS cockroach model is an important
393 new addition to the repertoire of invertebrate hosts for mammalian pathogens.

394 **5 Methods**

395 All work described in this manuscript was approved by the appropriate institutional review
396 board prior to completion. Since OS cockroaches are invertebrate animals, IACUC approval
397 was not necessary.

398 **5.1 Bacterial Strains and Knockout Construction**

399 *F. tularensis* LVS strains used in this study were provided by two different laboratories. The
400 strain designated as *F. tularensis* LVS-1 was provided by the J.F. Huntley laboratory at the
401 University of Toledo (from ATCC). LVS-1 was the parental strain use to generate both *ΔdsbA*
402 and *ΔdipA* mutants. The strain designated as *F. tularensis* LVS-2 was provided by the J.
403 Horzempa laboratory at West Liberty University (originally provided by Karen Elkins). LVS-
404 2 was the parental strain used to generate both *ΔdeoB* and *ΔiglC* mutants. None of the mutants
405 used in this study exhibited *in vitro* growth defects.

406 Generation of isogenic deletion mutants of *dsbA*, *dipA*, and *deoB* was described previously
407 [42, 71, 72]. Markerless deletion *iglC* was accomplished by sequentially deleting codons 71-
408 140 of both copies of *iglC*. The entire open reading frame was not deleted to preserve
409 elements presumed to be required for expression of neighboring genes [73]. A 0.5 kb region
410 of the *F. tularensis* LVS chromosome consisting of DNA upstream of *iglC* and a portion of
411 the N-terminal coding sequence as was amplified using primer 1
412 (CATGGCATGCTAAGATTGGTAGTATTGTGGATGTCGAGTCG) and primer 2
413 (GTCGACGGTACCACCGGTTTATTATTAAGTAGCAGCAGCTGTAGCCG). An
414 additional region of the *F. tularensis* LVS chromosome consisting of the C-terminal coding
415 sequence of *iglC* as well as downstream DNA was amplified using primer 3
416 (TAATAATAAACCGGTGGTACCGTCGACCTATCTAATTTAGAGTTATATCCAATAA
417 GTGC) and primer 4 (CATGCTGCAGCTTATCAGTCATTATTTGTAAAGATAACGG).
418 The two 0.5 kb amplicons were cloned into pJH1 [72] adjacent to each other to generate

419 pJH1 Δ iglC. This plasmid was mobilized into *F. tularensis* LVS using triparental mating as we
420 have done previously [72, 63]. Isolated merodiploids were electroporated with pGUTS to
421 force resolution. Deletion of a single *iglC* allele was confirmed by PCR (data not shown).
422 After a strain was isolated in which a single copy of *iglC* was deleted, pGUTS was cured as
423 previously described [72], and pJH1 Δ iglC was subsequently re-introduced by triparental
424 mating. PCR was used to confirm the recombination of this plasmid into DNA neighboring
425 the intact *iglC* allele (data not shown). Again, pGUTS was introduced into isolated
426 merodiploids by electroporation [72]. Deletion of the second *iglC* allele was confirmed by
427 PCR and western blotting (data not shown). Subsequently, pGUTS was cured as was
428 described previously [72, 63]. The resulting *iglC*-null mutant strain is referred to as Δ iglC.

429 **5.2 Bacterial Growth Conditions**

430 All *F. tularensis* isolates and mutant derivatives were maintained as permanent frozen stocks at
431 -80°C in BHI broth supplemented with 15% glycerol. For each experiment, bacteria were
432 recovered by streak plating onto Chocolate II agar (GC base with 1% isovitalax and 1%
433 Hemoglobin) and incubated at 37°C for 48 hours. Since the mutant strains used are genetically
434 stable, antibiotics were not added to the growth media prior to infections.

435 **5.3 Cockroach Housing**

436 The original laboratory stock of *Blaptica dubia* cockroaches was purchased from Backwater
437 Reptiles (www.backwaterreptiles.com). Subsequent generations that were reared in the lab were
438 used for most experiments, although we did supplement our stock with additional orders from
439 Backwater Reptiles, as necessary. Cockroaches were stored in vented 18- or 32-gallon plastic
440 containers and kept at 30°C in the dark. Since *B. dubia* cockroaches do not climb vertical glass
441 or slick plastic surfaces, no chemical or physical restrains are needed to keep the insects in the
442 rearing containers. Pressed paper egg cartons or paper-based cat litter
443 (www.yesterdaysnews.com) was used as a substrate in the rearing containers. Rearing

444 containers were cleaned and cockroaches were sorted into new containers according to their
445 developmental stage at least monthly, or more frequently as needed. Dry dog chow (Purina)
446 was provided *ad libitum* and fresh fruits or vegetables including carrots, oranges, bananas and
447 apples were given periodically as a source of water. After infection, groups of 4 or 5
448 cockroaches were kept in 100 mm Petri dishes with dry dog food and carrot slices, which were
449 changed daily.

450 **5.4 Bacterial Infection**

451 Newly molted, sixth-instar cockroaches weighing 0.7-1.0 g were transferred to the challenge
452 temperature (usually 37°C) at least seven days prior to infection in order to allow them to
453 acclimate. We found this acclimation step to be critical—cockroaches that experienced a
454 simultaneous temperature shift and injection trauma tended to have unpredictable deaths in
455 control groups and dose-independent deaths in experimental groups (data not shown). All data
456 reported here is from temperature-acclimated insects. Bacterial suspensions of approximately
457 10^8 colony forming units (CFU) per mL were created by suspending 3-4 colonies from a
458 Chocolate II agar plate incubated at 37°C for 48 hours in PBS. These initial suspensions were
459 serial diluted in PBS and aliquots (20 μ l) of each dilution were delivered by intrahemoceol
460 injection to the right of the midline at the base of the third tergum (**Figure 1D**). A 28-gauge
461 needle-syringe combination was used for all experiments except those testing for antibiotic
462 rescue. Those experiments used a sharpened pipette tip, made by cutting a 60° bevel into a gel-
463 loading pipette with a razor blade prior to sterilization, for inoculation of bacteria. The rate of
464 mortality in groups receiving 10^6 CFU of *F. tularensis* LVS by each method was not
465 significantly different ($p > 0.05$), but we have not yet compared the two methods at lower doses.
466 Using sharpened pipette tips for bacterial delivery is advantageous because it lowers cost and
467 increases safety compared to the use of needle and syringe. In either case, the abdomen was
468 swabbed with 70% isopropanol prior to injection in order to lessen the risk of external

469 contamination. For each experiment, a control group was injected with PBS to observe effects
470 of trauma alone. Groups of 8 to 10 cockroaches were used for each experiment. Cockroaches
471 were stored at the temperature indicated in **Table 1** and observed for survival up to 10 days
472 post-inoculation. Cockroaches were considered dead when they displayed no response to touch.

473 **5.5 Antibiotic Administration**

474 Groups of 10 cockroaches were injected with *F. tularensis* LVS using sharpened gel-loading
475 pipette tips and treated with antibiotics at 2, 48, and 96 hours post infection. Two methods of
476 delivery were used for antibiotic administration; systemic injection and controlled feeding. For
477 systemic injection, 20 μ l of each antibiotic suspension was injected into the base of the third
478 terga (abdominal plate) on the ventral side of the body, on the right side halfway between the
479 midline and the spiracle (**Figure 6A**) using a needle and syringe combination. For the second
480 and third injections, the left side of the same tergum and the right side of the next anterior
481 tergum were used, respectively. For controlled feeding, antibiotics were prepared and diluted
482 to the appropriate concentration in a sterile 50% sucrose solution. Cockroaches were placed on
483 their back and a 10 μ l aliquot of the sucrose solution containing antibiotic was slowly dispensed
484 onto the mouth (**Figure 6B**). This resulted in the rapid consumption of the entire dose.
485 Antibiotics were delivered at the following total doses, regardless of route: Streptomycin, 32
486 μ g; Gentamicin, 32 μ g; Doxycycline, 32 μ g; Azithromycin, 100 μ g; Resazurin; 11 μ g.

487 **5.6 Enumeration of bacteria in hemolymph**

488 *B. dubia* roaches were inoculated with 10^6 *F. tularensis* LVS cells as described previously.
489 Cockroaches were incubated at 37°C with access to dry dog chow and carrot slices (to prevent
490 dehydration). Hemolymph was extracted from insects at each designated time point of 6, 12,
491 24, 50, 72, and 96 hours post initial infection. Two groups were used for each extraction time
492 point. One group of cockroaches received a 16 μ g dose of gentamicin 2 hours prior to
493 hemolymph extraction, and a second group received an equal volume of sterile PBS in

494 parallel. At the time of harvest, cockroaches were cleansed with 70% isopropyl alcohol and
495 decapitated using sterile surgical scissors. Hemolymph was immediately drained into a 1.5
496 mL Eppendorf tube containing 10 μ l chilled PBS with anticoagulant (0.05% N-
497 Phenylthiourea). Tubes were weighed before and after addition of hemolymph in order to
498 estimate the volume of hemolymph collected from each cockroach. (This approach is necessary
499 because cockroach hemolymph is extremely viscous and cannot be accurately measured
500 volumetrically. We estimate that 1 ml \approx 1 g at room temperature). In order to quantify the
501 number of *F. tularensis* LVS CFU present in the hemolymph, the harvested samples were
502 serial diluted 1:10 in PBS and aliquots of each dilution were plated on Chocolate II agar plates
503 supplemented with ampicillin and trimethoprim. The total number of *F. tularensis* LVS per
504 mL of hemolymph was determined based on the number of CFU observed from PBS-treated
505 cockroaches and the number of intracellular *F. tularensis* LVS per mL of hemolymph was
506 determined based on the number of CFU observed from gentamicin-treated cockroaches.

507 **5.7 LD₅₀ Estimation and Statistical analysis**

508 The R programming environment (version 3.2.1; [74]), accessed via the RStudio interactive
509 development environment [75], was used for all comparisons. Lethal doses 50% and
510 corresponding 95% confidence intervals were estimated by non-linear regression using the 'drc'
511 package [40]. Differences in survival outcome between groups that received equivalent doses
512 of *F. tularensis* with or without antibiotics were determined by log-rank (Mantel-Cox) analysis
513 using the 'survival' package [76, 77]. For analysis of *in vivo* growth patterns of *F. tularensis*
514 LVS, the mean, median, and interquartile range of each group was calculated using plot.ly [78].

515 **Acknowledgements**

516 B.E.E. and O.M. were partially supported by NIH Grant Number 5P30 GM103332 from the
517 National Institute of General Medicine (NIGMS) and the North Dakota State University
518 Agricultural Research Station (NDSU ARS). Generation of the *iglC* mutant was funded in

519 part by an Institutional Development Award (IDeA) from the National Institute of General
520 Medical Sciences of the National Institutes of Health (P20GM103434) and a grant from the
521 National Institutes of Health, National Institute of Allergy and Infectious Diseases
522 (5K22AI087703). Generation of the *dsbA* and *dipA* mutants was supported by the National
523 Institute of Allergy and Infectious Disease of the National Institutes of Health
524 grants K22AI083372 and R01AI093351 to J.F.H. The contents of this manuscript are solely
525 the responsibility of the authors and do not necessarily represent the official views of the NIH,
526 the NDSU ARS, or Southern Research.


527 References

- 528 [1] T Morner and E Addison. Tularemia. In ES Williams and IK Barker, editors, *Infectious Diseases of*
529 *Wild Mammals*, chapter 18. Iowa State University Press, Ames, Iowa, USA, 3 edition, 2001. doi:
530 10.1002/9780470344880.ch18.
- 531 [2] J Thelaus, A Andersson, T Broman, S Bäckman, M Granberg, L Karlsson, K Kuoppa, E Larsson,
532 E Lundmark, JO Lundström, P Mathisen, J Näslund, M Schäfer, T Wahab, and M Forsman. Francisella
533 tularensis subspecies holarctica occurs in Swedish mosquitoes, persists through the developmental stages of
534 laboratory-infected mosquitoes and is transmissible during blood feeding. *Microb Ecol*, 67:96–107, Jan
535 2014.
- 536 [3] JO Lundström, AC Andersson, S Bäckman, ML Schäfer, M Forsman, and J Thelaus. Transstadial
537 transmission of Francisella tularensis holarctica in mosquitoes, Sweden. *Emerg Infect Dis*, 17:794–9, May
538 2011.
- 539 [4] R Asare, C Akimana, S Jones, and Kwaik Y Abu. Molecular bases of proliferation of Francisella
540 tularensis in arthropod vectors. *Environ Microbiol*, 12:2587–612, Sep 2010.
- 541 [5] JM Petersen, PS Mead, and ME Schriefer. Francisella tularensis: an arthropod-borne pathogen. *Vet Res*,
542 40:7, Mar 2009.
- 543 [6] RJ Mani, MV Reichard, RJ Morton, KM Kocan, and KD Clinkenbeard. Biology of Francisella
544 tularensis subspecies holarctica live vaccine strain in the tick vector Dermacentor variabilis. *PLoS One*,
545 7:e35441, null 2012.
- 546 [7] HK Goethert and SR 3rd Telford. Differential mortality of dog tick vectors due to infection by diverse
547 Francisella tularensis tularensis genotypes. *Vector Borne Zoonotic Dis*, 11:1263–8, Sep 2011.
- 548 [8] T Broman, J Thelaus, AC Andersson, S Bäckman, P Wikström, E Larsson, M Granberg, L Karlsson,
549 E Bäck, H Eliasson, R Mattsson, A Sjöstedt, and M Forsman. Molecular Detection of Persistent Francisella
550 tularensis Subspecies holarctica in Natural Waters. *Int J Microbiol*, 2011, null 2011.
- 551 [9] SM Reese, G Dietrich, MC Dolan, SW Sheldon, J Piesman, JM Petersen, and RJ Eisen. Transmission
552 dynamics of Francisella tularensis subspecies and clades by nymphal Dermacentor variabilis (Acari:
553 Ixodidae). *Am J Trop Med Hyg*, 83:645–52, Sep 2010.
- 554 [10] SM Reese, JM Petersen, SW Sheldon, MC Dolan, G Dietrich, J Piesman, and RJ Eisen.
555 Transmission efficiency of Francisella tularensis by adult american dog ticks (Acari: Ixodidae). *J Med*
556 *Entomol*, 48:884–90, Jul 2011.
- 557 [11] M Santic and Kwaik Y Abu. Nutritional virulence of Francisella tularensis. *Front Cell Infect*
558 *Microbiol*, 3:112, null 2013.
- 559 [12] S Steele, J Brunton, B Ziehr, S Taft-Benz, N Moorman, and T Kawula. Francisella tularensis
560 harvests nutrients derived via ATG5-independent autophagy to support intracellular growth. *PLoS Pathog*,
561 9:e1003562, Aug 2013.
- 562 [13] A Chong and J Celli. The francisella intracellular life cycle: toward molecular mechanisms of
563 intracellular survival and proliferation. *Front Microbiol*, 1:138, null 2010.
- 564 [14] CE Bradburne, AB Verhoeven, GC Manyam, SA Chaudhry, EL Chang, DC Thach, CL Bailey,
565 and Hoek ML van. Temporal transcriptional response during infection of type II alveolar epithelial cells

- 566 with *Francisella tularensis* live vaccine strain (LVS) supports a general host suppression and bacterial
567 uptake by macropinocytosis. *J Biol Chem*, 288:10780–91, Apr 2013.
- 568 [15] H Abd, T Johansson, I Golovliov, G Sandström, and M Forsman. Survival and growth of
569 *Francisella tularensis* in *Acanthamoeba castellanii*. *Appl Environ Microbiol*, 69:600–6, Jan 2003.
- 570 [16] CM Lauriano, JR Barker, SS Yoon, FE Nano, BP Arulanandam, DJ Hassett, and KE Klose.
571 *MglA* regulates transcription of virulence factors necessary for *Francisella tularensis* intraamoebae and
572 intramacrophage survival. *Proc Natl Acad Sci U S A*, 101:4246–9, Mar 2004.
- 573 [17] SH El-Etr, JJ Margolis, D Monack, RA Robison, M Cohen, E Moore, and A Rasley.
574 *Francisella tularensis* type A strains cause the rapid encystment of *Acanthamoeba castellanii* and survive in
575 amoebal cysts for three weeks postinfection. *Appl Environ Microbiol*, 75:7488–500, Dec 2009.
- 576 [18] J Ellis, PC Oyston, M Green, and RW Titball. Tularemia. *Clin Microbiol Rev*, 15:631–46, Oct
577 2002.
- 578 [19] DT Dennis, TV Inglesby, DA Henderson, JG Bartlett, MS Ascher, E Eitzen, AD Fine,
579 AM Friedlander, J Hauer, M Layton, SR Lillibridge, JE McDade, MT Osterholm, T O’Toole, G Parker,
580 TM Perl, PK Russell, and K Tonat. Tularemia as a biological weapon: medical and public health
581 management. *JAMA*, 285:2763–73, Jun 2001.
- 582 [20] DS Burke. Immunization against tularemia: analysis of the effectiveness of live *Francisella*
583 *tularensis* vaccine in prevention of laboratory-acquired tularemia. *J Infect Dis*, 135:55–60, Jan 1977.
- 584 [21] Hernández Y López, D Yero, JM Pinos-Rodríguez, and I Gibert. Animals devoid of pulmonary
585 system as infection models in the study of lung bacterial pathogens. *Front Microbiol*, 6:38, null 2015.
- 586 [22] E Bangi. *Drosophila* at the intersection of infection, inflammation, and cancer. *Front Cell*
587 *Infect Microbiol*, 3:103, null 2013.
- 588 [23] M Arvanitis, J Glavis-Bloom, and E Mylonakis. Invertebrate models of fungal infection.
589 *Biochim Biophys Acta*, 1832:1378–83, Sep 2013.
- 590 [24] N Ramarao, C Nielsen-Leroux, and D Lereclus. The insect *Galleria mellonella* as a powerful
591 infection model to investigate bacterial pathogenesis. *J Vis Exp*, page e4392, Dec 2012.
- 592 [25] MG Moule, DM Monack, and DS Schneider. Reciprocal analysis of *Francisella novicida*
593 infections of a *Drosophila melanogaster* model reveal host-pathogen conflicts mediated by reactive oxygen
594 and imd-regulated innate immune response. *PLoS Pathog*, 6:e1001065, Aug 2010.
- 595 [26] MK Ahlund, P Rydén, A Sjöstedt, and S Stöven. Directed screen of *Francisella novicida*
596 virulence determinants using *Drosophila melanogaster*. *Infect Immun*, 78:3118–28, Jul 2010.
- 597 [27] SN Dean and Hoek ML van. Screen of FDA-approved drug library identifies maprotiline, an
598 antibiofilm and antivirulence compound with QseC sensor-kinase dependent activity in *Francisella*
599 *novicida*. *Virulence*, 6:487–503, Jul 2015.
- 600 [28] N Sprynski, E Valade, and F Neulat-Ripoll. *Galleria mellonella* as an infection model for select
601 agents. *Methods Mol Biol*, 1197:3–9, null 2014.
- 602 [29] G Aperis, BB Fuchs, CA Anderson, JE Warner, SB Calderwood, and E Mylonakis. *Galleria*
603 *mellonella* as a model host to study infection by the *Francisella tularensis* live vaccine strain. *Microbes*
604 *Infect*, 9:729–34, May 2007.
- 605 [30] J Horzempa, PE Jr Carlson, DM O’Dee, RM Shanks, and GJ Nau. Global transcriptional
606 response to mammalian temperature provides new insight into *Francisella tularensis* pathogenesis. *BMC*
607 *Microbiol*, 8:172, Oct 2008.
- 608 [31] HA Shaik and F Sehna. Hemolin expression in the silk glands of *Galleria mellonella* in
609 response to bacterial challenge and prior to cell disintegration. *J Insect Physiol*, 55:781–7, Sep 2009.
- 610 [32] D Woltedji, Y Fang, B Han, M Feng, R Li, X Lu, and J Li. Proteome analysis of hemolymph
611 changes during the larval to pupal development stages of honeybee workers (*Apis mellifera ligustica*). *J*
612 *Proteome Res*, 12:5189–98, Nov 2013.
- 613 [33] Q Xu, A Lu, G Xiao, B Yang, J Zhang, X Li, J Guan, Q Shao, BT Beerntsen, P Zhang,
614 C Wang, and E Ling. Transcriptional profiling of midgut immunity response and degeneration in the
615 wandering silkworm, *Bombyx mori*. *PLoS One*, 7:e43769, null 2012.
- 616 [34] KD Seed and JJ Dennis. Development of *Galleria mellonella* as an alternative infection model
617 for the *Burkholderia cepacia* complex. *Infect Immun*, 76:1267–75, Mar 2008.
- 618 [35] RJ Thomas, KA Hamblin, SJ Armstrong, CM Müller, M Bokori-Brown, S Goldman,
619 HS Atkins, and RW Titball. *Galleria mellonella* as a model system to test the pharmacokinetics and
620 efficacy of antibiotics against *Burkholderia pseudomallei*. *Int J Antimicrob Agents*, 41:330–6, Apr 2013.
- 621 [36] CA García, ES Alcaraz, MA Franco, and de Rossi BN Passerini. Iron is a signal for
622 *Stenotrophomonas maltophilia* biofilm formation, oxidative stress response, OMPs expression, and
623 virulence. *Front Microbiol*, 6:926, 2015.
- 624 [37] J Stahl, H Bergmann, S Göttig, I Ebersberger, and B Averhoff. Acinetobacter baumannii
625 Virulence Is Mediated by the Concerted Action of Three Phospholipases D. *PLoS One*, 10:e0138360, 2015.

- 626 [38] F Obata, E Kuranaga, K Tomioka, M Ming, A Takeishi, CH Chen, T Soga, and M Miura.
627 Necrosis-driven systemic immune response alters SAM metabolism through the FOXO-GNMT axis. *Cell*
628 *Rep*, 7:821–33, May 2014.
- 629 [39] NA Fisher, WJ Ribot, W Applefeld, and D DeShazer. The Madagascar hissing cockroach as a
630 novel surrogate host for *Burkholderia pseudomallei*, *B. mallei* and *B. thailandensis*. *BMC Microbiol*,
631 12:117, Jun 2012.
- 632 [40] C. Ritz and J. C. Streibig. Bioassay Analysis using R. *Journal of Statistical Software*, 12, 2005.
- 633 [41] M Schmidt, J Klimentova, P Rehulka, A Straskova, P Spidlova, B Szotakova, J Stulik, and
634 I Pavkova. *Francisella tularensis* subsp. *holarctica* DsbA homologue: a thioredoxin-like protein with
635 chaperone function. *Microbiology*, 159:2364–74, Nov 2013.
- 636 [42] G Ren, MM Champion, and JF Huntley. Identification of disulfide bond isomerase substrates
637 reveals bacterial virulence factors. *Mol Microbiol*, 94:926–44, Nov 2014.
- 638 [43] A Chong, R Child, TD Wehrly, D Rockx-Brouwer, A Qin, BJ Mann, and J Celli. Structure-
639 Function Analysis of DipA, a *Francisella tularensis* Virulence Factor Required for Intracellular
640 Replication. *PLoS One*, 8:e67965, 2013.
- 641 [44] I Golovliov, A Sjöstedt, A Mokrievich, and V Pavlov. A method for allelic replacement in
642 *Francisella tularensis*. *FEMS Microbiol Lett*, 222:273–80, May 2003.
- 643 [45] J Horzempa, DM O’Dee, DB Stolz, JM Franks, D Clay, and GJ Nau. Invasion of erythrocytes
644 by *Francisella tularensis*. *J Infect Dis*, 204:51–9, Jul 2011.
- 645 [46] K Booth, L Cambron, N Fisher, and KJ Greenlee. Immune Defense Varies within an Instar in
646 the Tobacco Hornworm, *Manduca sexta**. *Physiol Biochem Zool*, 88:226–36, Mar 2015.
- 647 [47] I Eleftherianos, H Baldwin, RH French Constant, and SE Reynolds. Developmental
648 modulation of immunity: changes within the feeding period of the fifth larval stage in the defence reactions
649 of *Manduca sexta* to infection by *Photographus*. *J Insect Physiol*, 54:309–18, Jan 2008.
- 650 [48] L Tian, E Guo, Y Diao, S Zhou, Q Peng, Y Cao, E Ling, and S Li. Genome-wide regulation of
651 innate immunity by juvenile hormone and 20-hydroxyecdysone in the *Bombyx* fat body. *BMC Genomics*,
652 11:549, Oct 2010.
- 653 [49] S Ahmad, L Hunter, A Qin, BJ Mann, and Hoek ML van. Azithromycin effectiveness against
654 intracellular infections of *Francisella*. *BMC Microbiol*, 10:123, Apr 2010.
- 655 [50] DM Schmitt, DM O’Dee, BN Cowan, JW Birch, LK Mazzella, GJ Nau, and J Horzempa. The
656 use of resazurin as a novel antimicrobial agent against *Francisella tularensis*. *Front Cell Infect Microbiol*,
657 3:93, 2013.
- 658 [51] SA Smith, JM Scimeca, and ME Mainous. Culture and maintenance of selected invertebrates
659 in the laboratory and classroom. *ILAR J*, 52:153–64, 2011.
- 660 [52] TM Bass, RC Grandison, R Wong, P Martinez, L Partridge, and MD Piper. Optimization of
661 dietary restriction protocols in *Drosophila*. *J Gerontol A Biol Sci Med Sci*, 62:1071–81, Oct 2007.
- 662 [53] OpenBugFarm. , 2015. Accessed: 2015-09-02.
- 663 [54] Best Bet Worm Kits Inc. , 2015. Accessed: 2015-09-15.
- 664 [55] PG Koehler, CA Strong, and RS Patterson. Rearing improvements for the German cockroach
665 (Dictyoptera: Blattellidae). *J Med Entomol*, 31:704–10, Sep 1994.
- 666 [56] IH GILBERT. LABORATORY REARING OF COCKROACHES, BED-BUGS, HUMAN
667 LICE AND FLEAS. *Bull World Health Organ*, 31:561–3, 1964.
- 668 [57] K Meylaers, D Freitak, and L Schoofs. Immunocompetence of *Galleria mellonella*: sex- and
669 stage-specific differences and the physiological cost of mounting an immune response during
670 metamorphosis. *J Insect Physiol*, 53:146–56, Feb 2007.
- 671 [58] I Wojda and P Taszłow. Heat shock affects host-pathogen interaction in *Galleria mellonella*
672 infected with *Bacillus thuringiensis*. *J Insect Physiol*, 59:894–905, Sep 2013.
- 673 [59] S Kaunisto, L Härkönen, MJ Rantala, and R Kortet. Early-life temperature modifies adult
674 encapsulation response in an invasive ectoparasite. *Parasitology*, 142:1290–6, Sep 2015.
- 675 [60] AS Torson, GD Yocum, JP Rinehart, WP Kemp, and JH Bowsher. Transcriptional responses
676 to fluctuating thermal regimes underpinning differences in survival in the solitary bee *Megachile rotundata*.
677 *J Exp Biol*, 218:1060–8, Apr 2015.
- 678 [61] N Browne, C Surlis, and K Kavanagh. Thermal and physical stresses induce a short-term
679 immune priming effect in *Galleria mellonella* larvae. *J Insect Physiol*, 63:21–6, Apr 2014.
- 680 [62] M Telonis-Scott, Heerwaarden B van, TK Johnson, AA Hoffmann, and CM Sgrò. New levels
681 of transcriptome complexity at upper thermal limits in wild *Drosophila* revealed by exon expression
682 analysis. *Genetics*, 195:809–30, Nov 2013.
- 683 [63] J Horzempa, DM O’Dee, RM Shanks, and GJ Nau. *Francisella tularensis* DeltapyrF mutants
684 show that replication in nonmacrophages is sufficient for pathogenesis in vivo. *Infect Immun*, 78:2607–19,
685 Jun 2010.

- 686 [64] DS Weiss, A Brotcke, T Henry, JJ Margolis, K Chan, and DM Monack. In vivo negative
687 selection screen identifies genes required for Francisella virulence. *Proc Natl Acad Sci U S A*, 104:6037–
688 42, Apr 2007.
- 689 [65] JE Bröms, L Meyer, K Sun, M Lavander, and A Sjöstedt. Unique substrates secreted by the
690 type VI secretion system of Francisella tularensis during intramacrophage infection. *PLoS One*, 7:e50473,
691 2012.
- 692 [66] HT Law, A Sriram, C Fevang, EB Nix, FE Nano, and JA Guttman. IglC and PdpA are
693 important for promoting Francisella invasion and intracellular growth in epithelial cells. *PLoS One*,
694 9:e104881, 2014.
- 695 [67] MT Silva and NT Pestana. The in vivo extracellular life of facultative intracellular bacterial
696 parasites: role in pathogenesis. *Immunobiology*, 218:325–37, Mar 2013.
- 697 [68] S Beetz, TK Holthusen, J Koolman, and T Trenczek. Correlation of hemocyte counts with
698 different developmental parameters during the last larval instar of the tobacco hornworm, Manduca sexta.
699 *Arch Insect Biochem Physiol*, 67:63–75, Feb 2008.
- 700 [69] L Horn, J Leips, and M Starz-Gaiano. Phagocytic ability declines with age in adult Drosophila
701 hemocytes. *Aging Cell*, 13:719–28, Aug 2014.
- 702 [70] P Verma and MG Tapadia. Immune response and anti-microbial peptides expression in
703 Malpighian tubules of Drosophila melanogaster is under developmental regulation. *PLoS One*, 7:e40714,
704 2012.
- 705 [71] X Wu, G Ren, and JF Huntley. Generating Isogenic Deletions (Knockouts) in Francisella
706 tularensis, a Highly-infectious and Fastidious Gram-negative Bacterium. *Bio Protoc*, 5:e1500, Jun
707 2015.
- 708 [72] J Horzempa, RM Shanks, MJ Brown, BC Russo, DM O’Dee, and GJ Nau. Utilization of an
709 unstable plasmid and the I-SceI endonuclease to generate routine markerless deletion mutants in Francisella
710 tularensis. *J Microbiol Methods*, 80:106–8, Jan 2010.
- 711 [73] XH Lai, I Golovliov, and A Sjöstedt. Expression of IglC is necessary for intracellular growth
712 and induction of apoptosis in murine macrophages by Francisella tularensis. *Microb Pathog*, 37:225–30,
713 Nov 2004.
- 714 [74] R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for
715 Statistical Computing, Vienna, Austria, 2013.
- 716 [75] RStudio Team. *RStudio: Integrated Development Environment for R*. RStudio, Inc., Boston,
717 MA, 2015.
- 718 [76] Terry M. Therneau and Patricia M. Grambsch. *Modeling Survival Data: Extending the Cox
719 Model*. Springer, New York, 2000.
- 720 [77] Terry M Therneau. *A Package for Survival Analysis in S*, 2015. version 2.38.
- 721 [78] Plotly Technologies Inc. Collaborative data science, 2015.
- 722




723

724

725 **Figure 1.** (A) Wax worms purchased commercially that fail to produce silk casing when
726 transferred to a Petri dish. (B) Wax worms reared in the lab produce a thick silk casing when
727 removed from the primary culture vessel. (C) Juvenile (Ju), adult female (AF), and adult male
728 (AM) orange spotted cockroaches are easily distinguished from each other. Juveniles lack
729 wings while adult females have vestigial forewings that cover the first few abdominal
730 segments. Adult males have wings that extend the full length of their body, but they do not
731 fly. Pictured here in a standard 100 mm Petri dish. (D) Typical site of injection to the right of
732 the midline along the base of the third tergum (arrowhead) from the posterior. Note that
733 sharpened pipette tips can be used for inoculation, instead of needles.

734

735




736

737 **Figure 2. *B. dubia* survival is proportional to the *F. tularensis* LVS infection dose.** Groups
738 of juvenile OS cockroaches (n=8) were injected with either PBS (no bacteria) or serial
739 dilutions of *F. tularensis* LVS (1.7×10^6 to 10^3 CFU), incubated at 37°C, and monitored for
740 survival over the course of 7 days. LVS was grown on CHOCII agar for 48 hours, harvested,
741 and diluted in PBS. Statistical differences between groups were calculated by log-rank
742 (Mantel-Cox) analysis. Asterisks indicate significant difference from the no bacteria control
743 group (***)= $p < 0.001$.

744

745




746

747 **Figure 3. *F. tularensis* LVS lethality in *B. dubia* is temperature-dependent.** Groups of
748 juvenile *B. dubia* cockroaches (n=10) were injected with 6.0×10^6 CFU, 8.8×10^6 CFU, $4.5 \times$
749 10^6 CFU, or 3.0×10^6 CFU *F. tularensis* LVS (approx. 100 x LD₅₀) and incubated at 22°C,
750 30°C, 37°C, or 40°C, respectively. Statistical differences between groups were calculated by
751 log-rank (Mantel-Cox) analysis. Asterisks indicate statistical differences from the 37°C and
752 40°C groups (***) (***=p<0.001).

753

754




755

756 **Figure 4. *In vivo* growth of intracellular and total *F. tularensis* LVS in OS cockroaches.**

757 Total (open symbols) and gentamicin-protected (intracellular; shaded symbols) *F. tularensis*
 758 LVS from at least 5 infected OS cockroaches per time point. Bacterial CFU were determined
 759 by serial dilution of hemolymph and enumeration on CHOCII agar plates. Intracellular
 760 bacterial numbers were determined by injecting gentamicin into infected cockroaches 2 hours
 761 prior to each time point. Results from individual insects are shown as open (total CFU) and
 762 closed (intracellular CFU) circles. Boxes indicate the median (solid line), mean (dotted line)
 763 and interquartile ranges (IQR; box boundaries) for each group. Upper and lower whiskers
 764 correspond with the largest and smallest data points, respectively, within 1.5 x IQR for each
 765 group.

766

767




768

769 **Figure 5. OS cockroach susceptibility to *F. tularensis* infection varies by life stage.**

770 Groups of juvenile, adult male, or adult female cockroaches (n=10) were injected with 3.4×10^4 CFU *F. tularensis* LVS prior to incubation at 37°C. Statistical differences between groups
 771 were calculated by log-rank (Mantel-Cox) analysis. Asterisks indicate statistical differences
 772 from the adult male group (*=p<0.05; ***=p<0.001). Survival in the adult female and
 773 juvenile groups was not significantly different (p>0.05).
 774

775

776



777

778 **Figure 6. Antibiotic delivery to OS cockroaches.** (A) For systemic delivery, a 20 μ l aliquot
779 of each antibiotic or PBS vehicle control was injected at the base of the 3rd (shown) or 4th
780 tergum on the ventral side of the abdomen. (B) For oral delivery, cockroaches were placed on
781 their backs and were fed a solution containing either 50% sucrose or 50% sucrose containing
782 the specified antibiotic. In both cases, antibiotics were delivered at 2-, 48-, and 96-hours post
783 infection.

784

785

786 Tables

Strain	Host	Temperature	LD ₅₀ (95% CI), CFU
<i>F. tularensis</i> LVS-1	Juvenile cockroaches	22°C	3.2 × 10 ⁶ (5.6 × 10 ⁵ –1.2 × 10 ⁷)
	Juvenile cockroaches	30°C	2.9 × 10 ⁵ (4.6 × 10 ⁴ –1.8 × 10 ⁶)
	Juvenile cockroaches	37°C	3.5 × 10 ⁴ (1.1 × 10 ⁴ –1.0 × 10 ⁵)
	Juvenile cockroaches	40°C	1.2 × 10 ⁴ (4.2 × 10 ³ –3.3 × 10 ⁴)
	Adult female cockroaches	37°C	5.4 × 10 ⁴ (9.7 × 10 ³ –3.0 × 10 ⁵)
	Adult male cockroaches	37°C	1.3 × 10 ³ (4.0 × 10 ² –4.2 × 10 ³)
<i>F. tularensis</i> LVS-1 Δ <i>dsbA</i>	Juvenile cockroaches	37°C	2.2 × 10 ⁶ (1.0 × 10 ⁶ –4.7 × 10 ⁶)
<i>F. tularensis</i> LVS-1 Δ <i>dipA</i>	Juvenile cockroaches	37°C	8.1 × 10 ⁵ (4.0 × 10 ⁵ –1.6 × 10 ⁶)
<i>F. tularensis</i> LVS-2	Juvenile cockroaches	37°C	1.7 × 10 ⁴ (6.7 × 10 ³ –4.4 × 10 ⁴)
<i>F. tularensis</i> LVS-2 Δ <i>iglC</i>	Juvenile cockroaches	37°C	1.3 × 10 ⁶ (2.8 × 10 ⁵ –5.7 × 10 ⁶)
<i>F. tularensis</i> LVS-2 Δ <i>deoB</i>	Juvenile cockroaches	37°C	5.6 × 10 ⁵ (2.1 × 10 ⁵ –1.8 × 10 ⁶)
<i>E. coli</i> DH5α	Juvenile cockroaches	37°C	8.7 × 10 ⁶ (3.0 × 10 ⁶ –2.5 × 10 ⁷)

787

788 **Table 1. Median lethal dose of *F. tularensis* LVS and derivatives in OS cockroaches and**
789 **wax worms.** The median lethal dose (LD₅₀) of *F. tularensis* LVS parental strains, LVS-1 or
790 LVS-2, and deletion mutants of those LVS strains lacking known virulence factors, and *E.*
791 *coli* DH5α. LD₅₀ and corresponding 95% confidence intervals were estimated by non-linear
792 regression using the 'drc' package [40] in the R programming environment (Version 3.2.1).

793

794

Antibiotic	Route	Dose ^a	Survival Rate	Log-rank Comparison	
				to Vehicle Control	between Routes
Vehicle only	i.h.		0/18		
	p.o.		0/10		n.s.
Doxycycline	i.h.	32 µg	9/10	***	
	p.o.	32 µg	10/10	***	n.s.
Streptomycin	i.h.	32 µg	8/10	***	
	p.o.	32 µg	0/10	n.s.	**
Gentamicin	i.h.	32 µg	7/8	***	
	p.o.	32 µg	0/10	n.s.	***
Azithromycin	i.h.	100 µg	0/10	n.s.	
	p.o.	100 µg	0/10	n.s.	n.s.
Resazurin	i.h.	11 µg	0/10	n.s.	
	p.o.	11 µg	0/10	n.s.	n.s.
<u>Additional control groups</u>					
Bacteria only	No manipulation		0/10	n.s. ^b	
No Bacteria	No manipulation		10/10		
	i.h. vehicle		18/18		
	p.o. vehicle		6/6		

795

796 **Table 2. Rescue of OS cockroaches with antibiotics after lethal dose of *F. tularensis* LVS.**

797 Groups of OS cockroaches (n=8-18) were infected with approximately 100 x LD₅₀ (between
798 1.3 x 10⁶ CFU and 3.4 x 10⁶ CFU) *F. tularensis* LVS using sharpened pipette tips. Then at 2,
799 48, and 96 hours post-infection, infected cockroaches were treated by intrahemocoel injection
800 (i.h.) or peroral feeding (p.o.) of the antibiotics indicated. Statistical differences in survival
801 endpoints were determined by log-rank (Mantel-Cox) analysis. Asterisks indicate significant
802 differences compared to the corresponding vehicle control group or alternative route of
803 delivery (**=p<0.01, ***=p<0.001). ^a=this dose was administered three times during the
804 study. ^b=survival outcome in the no manipulation group was not statistically different than
805 survival in either vehicle control group (i.h. or p.o.; p>0.05 for all comparisons).

806